N-methyl-N-((1-methyl-5-(3-(1-(2-methylbenzyl)piperidin-4-yl)propoxy)-1H-indol-2-yl)methyl)prop-2-yn-1-amine, a new cholinesterase and monoamine oxidase dual inhibitor [PDF]
, 2014 On the basis of N-((5-(3-(1-benzylpiperidin-4-yl)propoxy)-1-methyl-1H-indol-2-yl)methyl)-N-methylprop-2-yn-1-amine (II, ASS234) and QSAR predictions, in this work we have designed, synthesized, and evaluated a number of new indole derivatives from which ...
Agbaba, D. +13 more
core +3 more sources
Intellectual autonomy, epistemic dependence and cognitive enhancement [PDF]
, 2017 Intellectual autonomy has long been identified as an epistemic virtue, one that has been championed influentially by (among others) Kant, Hume and Emerson.
Carter, J. Adam
core +1 more source
New N,N-dimethylcarbamate inhibitors of acetylcholinesterase: design synthesis and biological evaluation [PDF]
, 2016 A series of N,N-dimethylcarbamates containing a N,N-dibenzylamino moiety was synthesized and tested to evaluate their ability to inhibit Acetylcholinesterase (AChE).
Chiarotto, Isabella +9 more
core +1 more source
Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy [PDF]
, 2013 Introduction: Memantine and cholinesterase inhibitors potentially offer additional benefits in Alzheimer's disease (AD) when used together. This study assessed the efficacy and safety of combination treatment with memantine added to stable donepezil in ...
Atri, Alireza +5 more
core +1 more source
Potential implications of practice effects in Alzheimer's disease prevention trials. [PDF]
, 2017 IntroductionPractice effects (PEs) present a potential confound in clinical trials with cognitive outcomes. A single-blind placebo run-in design, with repeated cognitive outcome assessments before randomization to treatment, can minimize effects of ...
Ard, M Colin +5 more
core +1 more source
Efficacy of Ginkgo biloba as an adjunct to donepezil in amyloid PET-positive Alzheimer’s patients
Frontiers in NeurologyBackgroundGinkgo biloba is widely used in some regions as an adjunct therapy for Alzheimer’s disease (AD). Its potential mechanisms include antioxidative and anti-amyloid properties, yet clinical evidence remains mixed.ObjectiveWe investigated whether ...
YoungSoon Yang +2 more
doaj +1 more source
Molecular Medicine, 2023 Background Trastuzumab (Trz)-induced cardiotoxicity (TIC) is one of the most common adverse effects of targeted anticancer agents. Although oxidative stress, inflammation, mitochondrial dysfunction, apoptosis, and ferroptosis have been identified as ...
Thawatchai Khuanjing +8 more
doaj +1 more source
Journal of the Formosan Medical Association, 2022 Background: Donepezil had been recognized to have impact on sleep quality in demented patients. However, there was insufficient evidences about the actual effect of donepezil in the sleep architectures.
Cheng-Fang Hsieh +7 more
doaj +1 more source
Evaluating Response to High-Dose 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's Disease [PDF]
, 2015 AIMS: To identify factors predicting improvement/stabilization on the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) and investigate whether early treatment responses can predict long-term outcomes, during a ...
Farlow, Martin R. +4 more
core +1 more source
Low-Cost Portable Light Therapy for Alzheimer's Patients [PDF]
, 2019 This paper provides an overview of the information and research conducted that ushered the creation and innovation of a low-cost portable light therapy device to help treat Alzheimer’s patients.
Arasu, Melghi, Zoghi, Ben, Zoghi, Sara
core +1 more source